Vext Reports Solid Financial Results for Q3 2024
Vext Science reported Q3 2024 financial results with revenue of $9.0 million and Adjusted EBITDA of $2.9 million. The company saw a 14.2% sequential increase in consolidated retail sales, driven by adult-use sales growth in Ohio and market share gains in Arizona. Q3 performance showed significant improvement with Adjusted EBITDA margin reaching 32.0%, up from 12.9% in Q2 2024. The company is positioned to expand its Ohio footprint to reach the state dispensary license cap of 8, with new locations planned to open throughout 2025 and early 2026.
Vext Science ha riportato i risultati finanziari del Q3 2024, con ricavi di 9,0 milioni di dollari e un EBITDA Adjusted di 2,9 milioni di dollari. L'azienda ha registrato un aumento sequenziale del 14,2% nelle vendite al dettaglio consolidate, grazie alla crescita delle vendite per uso adulto in Ohio e all'aumento della quota di mercato in Arizona. Le performance del Q3 hanno mostrato un miglioramento significativo, con il margine EBITDA Adjusted che ha raggiunto il 32,0%, in aumento rispetto al 12,9% del Q2 2024. L'azienda è posizionata per espandere la sua presenza in Ohio per raggiungere il limite di 8 licenze per dispensari statali, con nuove location previste per l'apertura nel 2025 e all'inizio del 2026.
Vext Science reportó los resultados financieros del tercer trimestre de 2024 con ingresos de 9,0 millones de dólares y un EBITDA ajustado de 2,9 millones de dólares. La empresa vio un aumento secuencial del 14,2% en las ventas minoristas consolidadas, impulsado por el crecimiento de las ventas de uso adulto en Ohio y ganancias en participación de mercado en Arizona. El desempeño del tercer trimestre mostró una mejora significativa, con un margen de EBITDA ajustado que alcanzó el 32,0%, frente al 12,9% en el segundo trimestre de 2024. La compañía está posicionada para expandir su presencia en Ohio para alcanzar el límite de 8 licencias de dispensario del estado, con nuevas ubicaciones planeadas para abrirse a lo largo de 2025 y principios de 2026.
Vext Science는 2024년 3분기 재무 결과를 발표했으며, 수익은 900만 달러, 조정 EBITDA는 290만 달러에 달했습니다. 이 회사는 오하이오에서 성인용 판매 성장과 애리조나에서의 시장 점유율 증가로 인해 consolidated 소매 매출이 14.2% 증가했습니다. 3분기 성과는 상당한 개선을 보여 조정 EBITDA 마진이 32.0%에 도달하며, 이는 2024년 2분기의 12.9%에서 증가한 수치입니다. 이 회사는 오하이오에서 8개의 주 면허 한도에 도달하기 위해 입지를 확장할 수 있는 위치에 있으며, 2025년과 2026년 초에 새로운 매장을 개설할 계획입니다.
Vext Science a rapporté les résultats financiers du T3 2024, avec des revenus de 9,0 millions de dollars et un EBITDA ajusté de 2,9 millions de dollars. L'entreprise a enregistré une augmentation séquentielle de 14,2% des ventes de détail consolidées, soutenue par la croissance des ventes pour usage adulte dans l'Ohio et des gains de parts de marché en Arizona. Les performances du T3 ont montré une amélioration significative, avec une marge EBITDA ajustée atteignant 32,0%, en hausse par rapport à 12,9% au T2 2024. L'entreprise est positionnée pour étendre sa présence en Ohio afin d'atteindre le plafond de 8 licences de dispensaire de l'État, avec de nouveaux emplacements prévus pour ouvrir tout au long de 2025 et au début de 2026.
Vext Science hat die Finanzergebnisse für das 3. Quartal 2024 veröffentlicht, mit Einnahmen von 9,0 Millionen Dollar und einem bereinigten EBITDA von 2,9 Millionen Dollar. Das Unternehmen verzeichnete einen sequenziellen Anstieg der konsolidierten Einzelhandelsverkäufe um 14,2%, angetrieben durch das Wachstum der Verkäufe für den Erwachsenengebrauch in Ohio und Marktanteilsgewinne in Arizona. Die Leistung im 3. Quartal zeigte eine signifikante Verbesserung, mit einer bereinigten EBITDA-Marge von 32,0%, die im Vergleich zu 12,9% im 2. Quartal 2024 gestiegen ist. Das Unternehmen ist gut positioniert, um seine Präsenz in Ohio auszubauen und das staatliche Lizenzlimit von 8 zu erreichen, wobei neue Standorte für die Eröffnung im Jahr 2025 und Anfang 2026 geplant sind.
- Revenue increased to $9.0M in Q3 2024 from $8.4M in Q2 2024
- Adjusted EBITDA grew significantly to $2.9M from $1.1M in Q2 2024
- Adjusted EBITDA margin improved to 32.0% from 12.9% in previous quarter
- 14.2% sequential increase in consolidated retail sales
- Ohio retail stores performing at or above state averages
- Net loss of $2.5M in Q3 2024
- Ongoing supply-demand imbalance and pricing pressures in Arizona market
- Persistent macroeconomic headwinds affecting operations
- Generated
$9.0 million in revenue and Adjusted EBITDA1 of$2.9 million , driven by early growth from rollout of adult-use sales in Ohio, market share gains in Arizona and disciplined cost control. - Well positioned to continue to grow revenue and cash flow from fully vertically integrated Ohio footprint. Upon closing of previously announced acquisitions2 and completion of additional licensing under state law for the Tier 1 cultivation facility, Vext anticipates reaching the state dispensary license cap of 8, with dispensaries expected to open during 2025 and early into 2026.
Vancouver, British Columbia--(Newsfile Corp. - November 21, 2024) - Vext Science, Inc. (CSE: VEXT) (OTCQX: VEXTF) ("VEXT" or the "Company") a U.S.-based cannabis operator with vertical operations in Arizona and Ohio, today reported its financial results for the period ended September 30, 2024. All currency references used in this news release are in U.S. currency unless otherwise noted.
Summary Financial Results
| Q3 2024 | Q2 2024 | | Q3 2023 | | |||||
| Revenue | $ | 8,986,909 | $ | 8,426,928 | | $ | 8,099,285 | | |
| EBITDA1 | $ | 1,924,664 | $ | 171,309 | | $ | 404,358 | | |
| Adjusted EBITDA1 | $ | 2,873,020 | $ | 1,084,234 | | $ | 1,076,949 | | |
| Adjusted EBITDA Margin (%)1 |
Management Commentary
Eric Offenberger, CEO of Vext, commented, "Vext's performance in the third quarter of 2024 was testament to the team's disciplined execution amid persistent macroeconomic headwinds. Our solid Adjusted EBITDA results reflect both the transition to adult-use sales in Ohio, as well as our focus on maintaining strict cost control. Despite a challenging economic climate and typical third-quarter seasonality and pricing pressures in the Arizona market with the ongoing supply-demand imbalance, we're pleased to report that our economic unit volumes remain strong. This demonstrates the resilience of our business model and the strength of our customer relationships, positioning Vext favourably with customers as the Arizona market continues to stabilize."
"As anticipated, Ohio proved to be a key revenue driver this quarter. Vext retail stores performed at or above state averages, resulting in a
Q3 2024 Financial Results Conference Call
Vext will host a conference call and webcast on Thursday, November 21, 2024, at 08:00 a.m. ET. to discuss its third quarter 2024 financial results.
Date: November 21, 2024 | Time: 8:00 am E.T.
Participant Dial-in: +1-647-484-8814 or 1-844-763-8274
Replay Dial-in: +1-412-317-0088 or 1-855-669-9658
Conference ID: 10194423
Playback #: 7488060 (Expires on December 5, 2024)
Listen to webcast: https://www.gowebcasting.com/13849
For more details, visit Vext's investor website or contact the IR team at investors@vextscience.com.
Non-IFRS Financial Measures
This news release contains certain "non-IFRS financial measures" (equivalent to "non-GAAP financial measures", as such term is defined in National Instrument 52-112 - Non-GAAP and Other Financial Measures Disclosure ("NI 52-112")), "non-IFRS ratios" (equivalent to "non-GAAP ratios", as such term is defined in NI 52-112), including "EBITDA", "Adjusted EBITDA" and "Adjusted EBITDA margin". These financial measures do not have a standardized definition under IFRS, nor are they calculated or presented in accordance with IFRS and may not be comparable to similar measures presented by other companies. The Company defines EBITDA as earnings before interest, taxes, depreciation and amortization. The Company defines "Adjusted EBITDA" as net income (loss) from operations, as reported, before interest and tax, adjusted to exclude extraordinary items, non-recurring items, other non-cash items, including stock-based compensation expense, depreciation and amortization, foreign exchange and acquisition related costs, if applicable. The Company defines "Adjusted EBITDA margin" as Adjusted EBITDA divided by Revenue.
The Company has provided these financial measures as supplemental information and in addition to the financial measures that are calculated and presented in accordance with IFRS. The Company believes that these supplemental financial measures provide a valuable additional measure to use when analyzing the operating performance of the business. These supplemental financial measures should not be considered superior to, as a substitute for or as an alternative to, and should only be considered in conjunction with, the IFRS financial measures presented herein.
The following information provides reconciliations of the non-IFRS financial measures presented herein to the most directly comparable financial measures calculated and presented in accordance with IFRS.
| Q3 2024 | Q2 2024 | Q3 2023 | |||||||
| Revenue | $ | 8,986,909 | $ | 8,426,928 | $ | 8,099,285 | |||
| Net Income after taxes | $ | (2,496,768 | ) | $ | (4,390,035 | ) | $ | (1,838,204 | ) |
| Interest (Net) | 826,598 | 801,832 | 956,561 | ||||||
| Income Taxes | (238,844 | ) | (127,244 | ) | (1,064,372 | ) | |||
| Depreciation & Amortization | 3,833,678 | 3,886,756 | 2,350,373 | ||||||
| EBITDA | $ | 1,924,664 | $ | 171,309 | $ | 404,358 | |||
| Share-based compensation | 392,912 | 233,868 | 73,623 | ||||||
| Accretion | - | - | (5,983 | ) | |||||
| Share (Profit) / Loss on JVs | 121,335 | 118,370 | 47,777 | ||||||
| (Gain)/Loss on Asset Disposal | 1,912 | - | - | ||||||
| FV of WPCU loan | 612,086 | (104,150 | ) | 126,366 | |||||
| Loan costs EWB amortized | 44,287 | 44,827 | 44,287 | ||||||
| RSU Taxes | - | - | 4,274 | ||||||
| Foreign Exchange | (445 | ) | (910 | ) | 448 | ||||
| Change in FV of Biological | (223,731 | ) | 227,503 | 381,800 | |||||
| FV increment on acquired inventory sold | - | 393,417 | - | ||||||
| Adjusted EBITDA | $ | 2,873,020 | $ | 1,084,234 | $ | 1,076,949 | |||
| Adjusted EBITDA Margin (%)1 |
About VEXT Science, Inc.
Vext Science, Inc. is a U.S.-based cannabis operator with vertical operations in Arizona and Ohio. Vext's expertise spans from cultivation through to retail operations in its key markets. Based out of Arizona, Vext owns and operates state-of-the-art cultivation facilities, fully built-out manufacturing facilities as well as dispensaries in both Arizona and Ohio. The Company manufactures Vapen™, one of the leading THC concentrates, edibles, and distillate cartridge brands in Arizona. Its selection of award-winning products are created with Vext's in-house, high-quality flower and distributed across Arizona and Ohio, as well as through Vext's partnerships in other states. Vext's leadership team brings a proven track record of building and operating profitable multi-state operations, with the Company having operated profitably since 2016. The Company's primary focus is to continue growing in its core states of Arizona and Ohio, bringing together cutting-edge science, manufacturing, and marketing to provide a reliable and valuable customer experience while generating shareholder value.
Vext Science, Inc. is listed on the Canadian Securities Exchange under the symbol VEXT and trades on the OTCQX market under the symbol VEXTF. Learn more at www.vextscience.com and connect with Vext on Twitter/X and LinkedIn.
For more details on the Vapen brand:
Vapen website: VapenBrands.com
Instagram: @vapen
Facebook: @vapenbrands
Forward-Looking Statements
Statements in this news release that are forward-looking statements are subject to various risks and uncertainties concerning the specific factors disclosed here and elsewhere in Vext's periodic filings with Canadian securities regulators. When used in this news release, words such as "will, could, plan, estimate, expect, intend, may, potential, believe, should," and similar expressions, are forward-looking statements.
Forward-looking statements may include, without limitation, statements regarding future developments and the business and operations of Vext, including but not limited to the Company's transition to serve both the medical and adult-use markets in Ohio and the anticipated results therefrom, market projections of the cannabis industry in the jurisdictions in which the Company operates, and statements about the timing and completion of the Ohio Expansion Transaction, the acquisition of additional licenses and the opening of additional dispensaries in Ohio, all of which are subject to the risk factors contained in Vext's continuous disclosure filed on SEDAR+ at www.sedarplus.ca.
Although Vext has attempted to identify important factors that could cause actual results, performance or achievements to differ materially from those contained in the forward-looking statements, there can be other factors that cause results, performance or achievements not to be as anticipated, estimated or intended, including, but not limited to: dependence on obtaining regulatory approvals; being engaged in activities currently considered illegal under U.S. Federal laws; change in laws; reliance on management; requirements for additional financing; competition; hindered market growth and state adoption due to inconsistent public opinion and perception of the medical-use and adult-use marijuana industry; and regulatory or political change.
There can be no assurance that such information will prove to be accurate or that management's expectations or estimates of future developments, circumstances or results will materialize. Because of these risks and uncertainties, the results or events predicted in these forward-looking statements may differ materially from actual results or events.
Accordingly, readers should not place undue reliance on forward-looking statements. The forward-looking statements in this news release are made as of the date of this release. Vext disclaims any intention or obligation to update or revise such information, except as required by applicable law, and Vext does not assume any liability for disclosure relating to any other company mentioned herein.
The Canadian Securities Exchange has not reviewed, approved or disapproved the content of this news release.
Eric Offenberger
Chief Executive Officer
844-211-3725
For further information:
Jonathan Ross, Vext Investor Relations
jon.ross@loderockadvisors.com
416-244-9851
SOURCE: Vext Science, Inc.
1 See "Non-IFRS Financial Measures" below for more information regarding Vext's use of non-IFRS financial measures and other reconciliations.
2 Vext has executed an asset purchase agreement (as amended from time to time, the "Asset Purchase Agreement"), together with other definitive agreements (together with the Asset Purchase Agreement, the "Definitive Agreements"), with the members of Big Perm's Dispensary Ohio, LLC ("Big Perm") to acquire from Big Perm two cannabis dispensaries located in Ohio, as well as all licenses and assets related to the business of such dispensaries, other than excluded assets, for cash consideration of
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/230784
FAQ
What was Vext Science (VEXTF) revenue in Q3 2024?
What was Vext Science (VEXTF) Adjusted EBITDA margin in Q3 2024?
How many dispensaries is Vext Science (VEXTF) planning to operate in Ohio?
What drove Vext Science (VEXTF) retail sales growth in Q3 2024?
